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A B S T R A C T
Background
Vitamin E is a dietary compound that functions as an antioxidant scavenging toxic free radicals. Evidence that free radicals may
contribute to the pathological processes of cognitive impairment including Alzheimer’s disease has led to interest in the use of vitamin
E in the treatment of mild cognitive impairment (MCI) and Alzheimer’s dementia (AD).
Objectives
To assess the efficacy of vitamin E in the treatment of AD and prevention of progression of MCI to dementia.
Search methods
The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), The Cochrane Library, MEDLINE,
EMBASE, PsycINFO, CINAHL, LILACS as well as many trials databases and grey literature sources were searched on 25 June 2012
using the terms: “Vitamin E”, vitamin-E, alpha-tocopherol.
Selection criteria
All unconfounded, double-blind, randomised trials in which treatment with vitamin E at any dose was compared with placebo for
patients with AD and MCI.
Data collection and analysis
Two review authors independently applied the selection criteria and assessed study quality and extracted and analysed the data. For
each outcome measure data were sought on every patient randomised. Where such data were not available an analysis of patients who
completed treatment was conducted. It was not possible to pool data between studies owing to a lack of comparable outcome measure.
Main results
Only three studies met the inclusion criteria: two in an AD population and one in an MCI population. In the first of the AD studies (
Sano 1996) the authors reported some benefit from vitamin E (2000 IU/day) with fewer participants reaching an end point of death,
institutionalisation, change to a Clinical Dementia Rating (CDR) of three, or loss of two basic activities of daily living within two
years. Of patients completing treatment, 58% (45/77) on vitamin E compared with 74% (58/78) on placebo reached one of the end
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points (odds ratio (OR) 0.49; 95% confidence interval (CI) 0.25 to 0.96). The second AD treatment study (Lloret 2009) explored the
effects of vitamin E (800 IU/day) on cognitive progression in relation to oxidative stress levels. Patients whose oxidative stress markers
were lowered by vitamin E showed no significant difference in the percentage change in Mini-Mental State Examination (MMSE)
score, between baseline and six months, compared to the placebo group. The primary aim of the MCI study (Petersen 2005) was to
investigate the effect of vitamin E (2000 IU/day) on the time to progression from MCI to possible or probable AD. A total of 214
of the 769 participants progressed to dementia, with 212 being classified as having possible or probable AD. There was no significant
difference in the probability of progression from MCI to AD between the vitamin E group and the placebo group (hazard ratio 1.02;
95% CI 0.74 to 1.41; P = 0.91).
Authors’ conclusions
No convincing evidence that vitamin E is of benefit in the treatment of AD or MCI. Future trials assessing vitamin E treatment in AD
should not be restricted to alpha-tocopherol.
P L A I N L A N G U A G E S U M M A R Y
Vitamin E should not be used for the treatment of mild cognitive impairment (MCI) and Alzheimer’s dementia (AD)
Vitamin E is a dietary compound that has strong antioxidant properties. Vitamin E has been shown to act on some toxic chemicals
that may contribute to the damage seen in AD. Many laboratory, animal and epidemiological studies have pointed towards a possible
beneficial role for vitamin E in the prevention and treatment of AD. However, to date very limited evidence exists in humans to support
the routine use of vitamin E. Further, in recent years evidence has come to light implicating vitamin E with potentially serious side
effects and even increased mortality. In this review three studies were identified and these demonstrated no or limited benefit for vitamin
E in MCI and AD. Therefore, vitamin E should not be used in the treatment of MCI or AD. More trials are still needed but these
should include different forms of vitamin E.
B A C K G R O U N D
Description of the condition
Alzheimer’s dementia (AD) is a progressive neurodegenerative dis-
ease resulting in deficits in multiple cognitive domains, including
memory, language and executive functioning, as well as a variety
of emotional and behavioural symptoms. This subsequently leads
to progressive functional impairment. AD causes huge emotional
and financial burden to patients, carers, and health and social care
systems. Current treatments for AD have limited efficacy and can-
not prevent progression of the condition. It is projected that one
in 85 people will suffer from the disease by 2050, equating to a
worldwide prevalence of 106.2 million cases (Brookmeyer 2007).
Mild cognitive impairment (MCI) is a condition that results in
cognitive deficits but does not meet the diagnostic criteria for
dementia. There has been much controversy over the status of
MCI; whether it is a discrete disorder, a continuation of normal
ageing or precursor to dementia. Regardless, what is known is
that those with MCI are at a greater risk of developing dementia
(Ganguli 2011). It is currently estimated that between 10% and
20% of people over the age of 65 years suffer fromMCI (Petersen
2011), which is expected to increase along with the increasing
prevalence rates of AD.
Description of the intervention
VitaminE is a generic term for a group of eight naturally occurring,
fat-soluble chemical derivatives of tocopherol and tocotrienol. Un-
til very recently, alpha-tocopherol was the most commonly stud-
ied compound. Vitamin E occurs in a variety of food substances
including vegetable oils and fats, and in nuts and seeds, such as al-
monds and sunflower seeds. However, alpha-tocopherol has been
the sole form of supplements used in clinical trials in AD. Ac-
cording to the Food and Nutrition Board (FNB) at the Institute
of Medicine of The National Academies (US) the recommended
daily allowance for men and women over 14 years of age is 22.4
IU (15 mg of alpha-tocopherol) (National Academy of Sciences
2000).
Vitamin E functions biologically as a scavenger of different free
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radicals by working as an antioxidant (Uneri 2006). Oxygen free
radicals contain oxygen atoms with unpaired electrons and are
highly reactive, damaging proteins, deoxyribonucleic acid (DNA)
and cell membranes unless rapidly ’quenched’ by antioxidants.
They are produced as by-products of the body’s metabolism as
well as by radiation. As vitamin E is lipophilic, it is able to pro-
tect cell membranes and plasma lipoproteins from peroxyl radi-
cals, which react with vitamin E preferentially (Traber 2011). In
particular vitamin E is thought to inhibit the process of lipid per-
oxidation, which damages the polyunsaturated fatty acids essential
to the integrity of cell membranes. Vitamin E activities in pro-
tecting against the deleterious effects of free radicals may be mea-
sured indirectly by assessing the state of the antioxidant-oxidant
system. Endogenous antioxidants such as glutathione provide an
indication of the antioxidant status while the oxidised form of glu-
tathione, glutathione disulphide (GSSG), and malondialdehyde
(MDA) may provide an indication of the oxidative stress status
and in particular lipid peroxidation.
High doses of vitamin E (over 3000 IU/day) are considered toxic,
and have been implicated in a variety of symptoms including fa-
tigue, gastrointestinal cramps and diarrhoea. Further, there is an
increasing body of evidence that vitamin E supplementation can
cause adverse effects, even at therapeutic doses. For example, vi-
tamin E increases bleeding tendency and can potentiate the effect
of aspirin (Steiner 1995). One meta-analysis found that vitamin E
supplementation, while reducing risk of ischaemic stroke by 10%,
increased the risk of haemorrhagic stroke by 22% (Schurks 2010).
Evidence from the Selenium and Vitamin E Cancer Prevention
Trial (SELECT) suggests that daily supplementation with 400 IU
vitamin E in healthy men may significantly increase the risk of
prostate cancer (Klein 2011) and there is evidence from the Heart
Outcomes Prevention Evaluation (HOPE) trial that vitamin E
supplementation increases the risk of heart failure and hospitalisa-
tion for heart failure in patients over 55 years of age with diabetes
mellitus and vascular disease (Lonn 2005). Miller 2005 carried
out a meta-analysis of 19 clinical trials testing vitamin E alone or
in combination with other supplements. The median dose of vita-
min E in these trials was 400 IU/day although the maximum dose
range was up to 2000 IU/day. The authors reported a statistically
significant dose-dependent relationship between vitamin E intake
and all-cause mortality. One Cochrane meta-analysis also found
that vitamin E given singly or combined significantly increased
mortality in 26 trials (risk ratio (RR) 1.04) (Bjelakovic 2010).
How the intervention might work
As summarised by Grundman 2000, there are both theoretical
reasons and empirical findings to suggest that free radical dam-
age may be one of the mechanisms causing neuronal degenera-
tion in a range of conditions including ageing, MCI and AD.
Many studies have found evidence of increased level of oxidative
damage to neurons and mitochondrial DNA in AD and MCI
(Butterfield 2002; Hensley 1995; Mecocci 1994; Mecocci 2004;
Marcus 1998; Wang 2005; Wang 2006). Antioxidants, including
vitamin E, improve cognitive functioning of aged rodents (Socci
1995), and protect against the effects of brain ischaemia (Hara
1990) and of some neurotoxins (Wortwein 1994).Transgenic mice
over-expressing the amyloid precursor protein (APP), implicated
in AD, show accelerated age-associated brain degeneration (Hsiao
1995). Vitamin E can delay this deterioration (Behl 1992; Koppal
1998; Zhou 1996) and decrease oxidative DNA damage (Boothby
2005).
Central nervous tissue contains a high proportion of fatty mate-
rial (lipid), and since vitamin E is fat-soluble it can readily enter
the brain (Vatassery 1988). In humans, there have been reports
of an association between low blood levels of vitamin E and im-
paired cognitive function (Ichitani 1992; Perrig 1997). However,
the studies of plasma and serum biomarkers including vitamin E
as an antioxidant are not conclusive or consistent for the treatment
of cognitive impairment (Irizarry 2004). Average levels of Vitamin
E in the blood and cerebrospinal fluid of patients with AD were
reported to be lower than normal in several reports (Jeandel 1989;
Jimenez-Jimenez 1997; Polidori 2002; Tohgi 1994; Zaman 1992)
though not in all (Ahlskog 1995). Lower levels of both forms of
vitamin E - tocotrienols and tocopherols - have been observed in
plasma of AD and MCI patients (Mangialasche 2012). However,
reported lower levels of vitamin E in AD may be due in part to
an overall decreased general dietary intake especially as the disease
advances (Tabet 2001; Tabet 2002).Hence, lower vitamin E blood
levels in AD may be a consequence of the disease rather than a
cause of it.
Results from clinical trials of vitamin E in non-AD neurodegener-
ative disorders have not been promising. For example, neither pa-
tients with Parkinson’s disease (Parkinson’s SG 1993, Pham 2005)
nor Huntington’s disease (Peyser 1995) have shown a significant
overall effect for vitamin E. In this review we focus specifically on
the role of vitamin E in the treatment of AD and MCI.
O B J E C T I V E S
To assess the efficacy of vitamin E in the treatment of AD and
MCI.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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All unconfounded, randomised, double-blind trials identified in
the search in which vitamin E was compared with placebo in the
treatment of patients with MCI or AD, or both, were studied.
Trials in which allocations to treatment were not randomised, or
in which treatment allocations were not concealed were excluded.
Types of participants
Participants for treatment of AD in included trials were diagnosed
with probable ADaccording to internationally accepted diagnostic
criteria including NINCDS-ADRDA (National Institute of Neu-
rological and Communicative Disorders and Stroke-Alzheimer’s
Disease and Related Disorders Association (McKhann 1984), Di-
agnostic and Statistical Manual of Mental Disorders, Fourth Edi-
tion (DSM-IV) (APA 1994) and International Statistical Classi-
fication of Diseases and Related Health Problem, Tenth Revision
(ICD 10). Participants in trials for prevention of progression to
AD should have MCI. In the absence of consensus on accepted
criteria, this could be defined either according to published criteria
such as those by Petersen 2005, or any other criterion with face
validity.
Types of interventions
Any dosage of vitamin E or any of its constituent tocopherols
or tocotrienols. Co-administration of another drug with vitamin
E was permitted if the same drug was also taken by the placebo
group.
Types of outcome measures
All outcome measures had to derive from validated, published
scales.
Primary outcomes
• Development of, or time to development of, possible AD
from MCI.
• Cognitive function.
• Adverse events.
• Death.
Secondary outcomes
• Global measure of severity and deterioration.
• Behavioural disturbance.
• Mood.
• Activities of daily living.
• Carer burden.
• Quality of life.
• Permanent physical disability.
• Institutionalisation.
Search methods for identification of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois) - the
Cochrane Dementia and Cognitive Improvement Group’s Spe-
cialized Register on 26 June 2012. The search terms used were:
“Vitamin E”, vitamin-E, alpha-tocopherol.
ALOIS is maintained by the Trials Search Co-ordinator of the
CochraneDementia and Cognitive ImprovementGroup and con-
tains studies in the areas of dementia prevention, dementia treat-
ment and cognitive enhancement in healthy. The studies are iden-
tified from:
1. monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO and
LILACS;
2. monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials and the Netherlands National Trials Register, plus
others);
3. quarterly searches of The Cochrane Library’s Central
Register of Controlled Trials (CENTRAL);
4. six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS
on the ALOIS website.
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ’methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Additional searches were performed in many of the sources listed
above to cover the timeframe from the last searches performed for
ALOIS to ensure that the search for the review was as up-to-date
and as comprehensive as possible. The search strategies used can
be seen in Appendix 1.
Data collection and analysis
Selection of studies
Three review authors (NF, MI, and NT) independently examined
the title and abstract of the papers identified by the search and
selected them for their relevance to the review. The selected cita-
tions were retrieved. All disagreements concerning inclusion were
resolved by discussion. Inclusion criteria were clearly defined.
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Data extraction and management
Data were extracted by one review author (NT for Sano study,
MI for Petersen study, and NF for Lloret study). An attempt was
made to collect the following data:
• report - author, year and source of publication;
• study - study setting;
• patients - demographics, diagnostic criteria for AD or MCI,
exclusion criteria, other concomitant medical conditions or
medications that may affect cognition;
• research design and features - sampling mechanism,
treatment assignment mechanism, blinding, drop-out rates,
length of follow-up, pertinent design features (e.g. cross-over
design);
• intervention - type, duration, dose, timing, mode of
delivery;
• outcome measures;
• results - number of patients randomised, outcome data.
For each outcome measure, data were sought on every patient ran-
domised. Intention-to-treat data were preferred. If these were not
available, data were extracted on patients who completed treat-
ment. Data were not extracted for any non-randomised titration
periods or any open-label follow-on phases.
For continuous data themeans, standard deviation (SD) and num-
ber of participants in each treatment group at each time point were
extracted. Change from baseline data were extracted if end-point
data were unavailable.
For binary data, the data extracted was the number of patients
with each outcome in each treatment group at each time point.
For ordinal data, there were two possible approaches. If ordinal
scale data appeared to be approximately normally distributed or if
the analysis that the investigators performed suggested that para-
metric tests were appropriate, then the outcome measures were
treated as continuous data. The second approach, which may not
exclude the first, was to concatenate into two categories that best
represent the contrasting states of interest, and to treat the variable
as binary.
For time-to-event data, a hazard ratio (HR) was sought.
Assessment of risk of bias in included studies
Risk of bias was assessed by NF and MI for each included study
was assessed based upon the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). The following criteria
were assessed:
• sequence generation;
• allocation concealment;
• blinding (participants);
• blinding (investigators);
• incomplete outcome reporting;
• selective outcome reporting.
For each study, a risk of bias rating (’Low risk’, ’Unclear risk’ or
’High risk’) was given for each of the above criteria. Empirical re-
search has shown that lack of adequate allocation concealmentmay
be associated with bias. Trials with unclear concealment measures
have been shown to yieldmore pronounced estimates of treatment
effects than trials that have taken adequate measures to conceal
allocation schedules, but less pronounced than inadequately con-
cealed trials (Chalmers 1983; Schulz 1995). Thus trials were in-
cluded if they conform to ’Low risk’ or ’Unclear risk’ allocation
risk categories, while those falling into ’High risk’ category were
excluded.
Measures of treatment effect
For studies with continuous outcome measures, mean differences
or standardised mean differences were calculated. For binary out-
comemeasures odds ratio (OR) were calculated. For time-to-event
outcome measures, HRs were calculated.
Unit of analysis issues
The participant was the unit of analysis. No cross-over studies were
identified.
Dealing with missing data
An intention-to-treat analysis was carried out where possible. In
cases where only completers’ data were available the impact of
the missing data on the findings was explored, where possible. A
sensitivity analysis was carried out in one study (Petersen 2005) to
investigate the impact of a high drop-out rate.
Assessment of heterogeneity
Owing to the significant clinical andmethodological heterogeneity
between studies, results were not synthesised and no statistical tests
for heterogeneity were performed.
Assessment of reporting biases
There was an insufficient number of studies identified to make
any quantitative assessment.
Data synthesis
It was not possible to synthesise and compare data across studies
as there were no comparable outcome measures.
Subgroup analysis and investigation of heterogeneity
Although not specified in the protocol, data were extracted and
reported for a subgroup analysis carried out in one included study.
The subgroupswere participants who did or did not show a decline
in markers of oxidative stress in response to vitamin E treatment.
This subgroup was considered important to include as a reduction
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of oxidative stress is thought to be themechanismbywhich vitamin
E may affect cognition.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Only three trials met the inclusion criteria: Lloret 2009, Petersen
2005 and Sano 1996. Two (Lloret 2009; Sano 1996) were trials
of alpha-tocopherol (vitamin E) for the treatment of AD and one
(Petersen2005)was a trial of alpha-tocopherol to delay progression
from amnestic MCI to dementia.
Treatment of Alzheimer’s dementia
The primary purpose of the first treatment study by Sano 1996 was
to determine whether selegiline (a monoamine oxidase inhibitor),
alpha-tocopherol (vitamin E) or a combination of the two agents
would slow the clinical deterioration associated with AD. Both
selegiline and vitamin E were tested using a factorial 2x2 design,
with four groups: placebo, selegiline (10 mg total daily dose di-
vided into two doses), vitamin E (2000 IU total daily dose divided
into two doses) and selegiline (10 mg total daily dose divided into
two doses) plus vitamin E (2000 IU total daily dose divided into
two doses). A total of 341 subjects with a diagnosis of probable AD
and with moderate severity (Clinical Dementia Rating (CDR) 2)
(Berg 1988), were recruited from 23 centres in the US. For fur-
ther details about the study refer to the Characteristics of included
studies.
Assessments were conducted one month after enrolment and at
three-monthly intervals for two years. The primary outcome was
the survival time to any one of four end points; death, institu-
tionalisation, change in severity of dementia to a CDR of three
or loss of two basic activities of daily living. After the primary
end point was reached, every effort was made to continue fur-
ther assessment of the secondary outcomes if possible. The sec-
ondary outcomes were; the cognitive part of the Alzheimer’s Dis-
ease Assessment Scale (ADAS-Cog) (Rosen 1984), Mini-Mental
State Examination (MMSE) (Folstein 1975), Blessed Dementia
Scale (BDS) (Blessed 1968), function was also measured using the
Dependence Scale (DS) (Stern 1994) and Behavior Rating Scale
for Dementia (BRSD) (Tariot 1995). The primary analysis com-
pared survival to end point for each of the three treatment groups
in comparison with the placebo group, using Kaplan-Meier es-
timation and log-rank tests with no correction for other factors
or variables, and the Cox proportional hazards model including
covariates. A small number of patients did not complete to the
primary end point (placebo 6/84, selegiline 4/87, vitamin E 8/85,
selegiline plus vitamin E 5/85). The secondary outcomes were as-
sessed at one month, and then every three months until two years.
The purpose of the second treatment study (Lloret 2009) was to
explore the effects of vitamin E on AD progression and mark-
ers of oxidative stress. Vitamin E (800 IU) or placebo was given
daily for six months. There were 57 participants diagnosed with
probable AD. All AD participants were taking a cholinesterase
inhibitor and were not on any other antioxidant medication. As-
sessments were conducted on the first day of enrolment and six
months after. Oxidative stress was assessed in two ways. The first
method used blood concentrations of the oxidised glutathione
molecule, GSSG, with greater levels indicating greater oxidative
stress. GSSG was also assessed as a ratio with the antioxidant
molecule glutathione. Further the blood marker MDA was mea-
sured as a marker of lipid peroxidation, which is a strong indi-
cator of oxidative damage. AD progression was measured by the
Clock drawing test (Sunderland 1989), the BDS (Blessed 1968)
and MMSE (Folstein 1975). For further details about the study
refer to the Characteristics of included studies.
The primary analysis was to compare performance on the cog-
nitive tasks in relation to the effects of vitamin E on oxidative
stress. Vitamin E-treated participants were divided into respon-
ders and non-responders according to whether vitamin E was ef-
fective or not in reducing markers of oxidative stress. The respon-
der, non-responder and placebo group means were compared us-
ing a Kruskal-Wallis test. Comparison between groups was also
undertaken following removal of participants with cerebrovascular
disease. To determine the effect of modifying oxidative stress on
cognitive performance - the relationship between MMSE change
and GSSG change in patients treated with vitamin E was assessed
using Spearman’s coefficient of correlation. The effects of vitamin
E on oxidative stress markers were investigated using a Mann-
Whitney test to compare GSSG andMDA values at the beginning
of the study and the end of the study in both the placebo and
active treatment conditions.
Prevention of progression of cognitive impairment
The primary purpose of the MCI study (Petersen 2005) was to
determine whether treatment with vitamin E (2000 IU/day) or
donepezil in subjects with the amnestic form of MCI decreased
the conversion rate into AD. There were three treatment groups:
vitamin E, donepezil and placebo. All participants were also tak-
ing a multivitamin. This review includes the vitamin E and the
placebo groups only. Out of a total of 769 subjects enrolled from
69 sites in the US and Canada, 516 received either placebo or
vitamin E intervention. The secondary outcomes were scores on
various measures: theMMSE (Folstein 1975), ADAS-Cog (Rosen
1984), CDR (sum of boxes), the Alzheimer’s Disease Assessment
ScaleMild Cognitive Impairment Activities of Daily Living Scale,
the Global Deterioration Scale, a neuropsychological battery, and
adverse events. For further details about the study design refer to
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the Characteristics of included studies.
The primary analysis was conducted according to an intention-
to-treat principle to determine whether there was a significant
reduction in time to progression to AD among subjects treated
with either vitamin E or donepezil as compared with those given
placebo. The Cox proportional-hazards model was used, and the
baseline variables were included in the analysis as covariates. Two
primary analyses were conducted, one comparing the vitamin E
and placebo groups, whichwas themain interest of this review, and
one comparing the donepezil and placebo groups. The Hochberg
method (Hochberg 1988) was used to adjust the two P values
for multiple comparisons. The Schoenfeld residuals test was used
to test for non-proportional hazards (Schoenfeld 1982). A z test
was used to compare estimated survival rates at various points
on the Kaplan-Meier curves (at 6, 12, 18, 24 and 36 months).
The Hochberg method was used to adjust the six P values for
multiple comparisons. Subgroup analysis for apolipoprotein E4
(ApoE4) carriers was conducted using HRs derived from the Cox
analysis. The secondary outcomes were examined with the use
of covariance for the change in the scores without correction for
multiple comparisons, and missing values were input with the use
of a projection method appropriate for assessing responses among
subjects with neurodegenerative diseases.
Risk of bias in included studies
Random sequence generation (selection bias)
We judged that all three studies had a low risk of bias.
Allocation (selection bias)
Concealment of participant allocation according to the randomi-
sation sequence was unclear in the three studies as they did not
clearly refer to how the ensured allocation concealment.
Blinding of participants and personnel (performance
bias)
All studies had an unclear risk of bias as they did not report what
steps were taken to ensure that participants and personnel re-
mained blinded to treatment allocation.
Blinding of outcome assessment (detection bias)
Only the Petersen2005 study reported evidence that assessors were
blinded to the outcomes. There were unclear risks of bias in the
Lloret 2009 and Sano 1996 studies as they did not refer to blinding
during outcome assessment.
Incomplete outcome data (attrition bias)
Only Petersen 2005 investigated the impact of the drop-out. Sano
1996 reported the attrition rate but did not give reasons, and hence
is judged as an unclear risk of bias. Lloret 2009 reported a very
high attrition rates and did not give reasons, as such it was judged
as a high risk of bias.
Selective reporting (reporting bias)
All studies reported outcomes stated in their protocol.
Other potential sources of bias
No other sources of bias were found.
See Figure 1 for the summary of the risk of bias.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
Treatment of Alzheimer’s dementia
The treatment study (Sano 1996) had four treatment groups, but
data from only two of the groups were evaluated. These were the
groups receiving placebo only and vitamin E only. The selegiline
and selegiline plus vitamin E groups were excluded because there
was no placebo control for the vitamin E.
Sano 1996 reported the number in each outcome group who
reached the primary end point within two years for the completers
only. The analysis of data of those reaching end point showed
benefit associated with vitamin E (58% (45/77) of patients in the
vitamin E group reached end point compared with 74% (58/78)
in the placebo group; OR 0.49; 95% confidence interval (CI) 0.25
to 0.96). Because the trial was limited in time, this analysis, com-
paring a count of events without taking into account the timing
of events, should still be valid but is less precise than the survival
analysis reported by Sano 1996. Using Kaplan-Meier estimation
and log-rank testing in their primary analysis, Sano 1996 found
no significant difference in survival time to one of the four end
points between the vitamin E and placebo groups (RR 0.70; P
= 0.08). However, the study groups differed in baseline MMSE
scores and these were correlated with clinical course. The vitamin
E group began with a mean MMSE of 11.3 (SD 5.7) and the
placebo group with a mean of 13.3 (SD 4.9). When the analy-
sis was repeated using the Cox proportional hazards model and
controlling for baseline MMSE a significant difference favouring
vitamin E emerged (RR 0.47; P = 0.001). No statistical analysis
was performed on secondary outcome measures data as only mean
change scores to the time point where a patient was last assessed
were reported and patients had been assessed over varying and
unidentified time spans.
Six patients from the placebo group and eight from the vitamin
E group were lost to follow-up before reaching an end point, but
there is no information on the time points at which these patients
were lost. A total of 49 categories of adverse events were defined
but the only results initially reported were for three categories, in
which significant differences between one ormore of the treatment
groups and the placebo group were found. However, once the
authors made adjustments for multiple comparisons no significant
differences between groups were found.
Lloret 2009 divided participants treated with vitamin E into two
groups depending on changes in oxidative stress markers with
treatment. Those who showed a decrease in GSSG values of more
than 10 nmol per mL of blood after six months of vitamin E treat-
ment were termed ’responders’ and those who did not were termed
’non-responders’. These groups had not been defined in advance
of data collection. They reported ’completers’ results only (33/
57 randomised patients). The percentage change in performance
from baseline to six months on the BDS, Clock drawing test and
MMSE were then compared across responders (N = 9), non-re-
sponders (N = 10) and placebo-treated groups (N = 14). There was
no significant difference reported between groups on the Clock
drawing test or BDS. The MMSE score increased in the respon-
der group but decreased in the placebo group and more so in the
non-responders. A significant difference was reported between the
two vitamin E-treated groups (P < 0.05). The responders did not
differ significantly from the placebo-treated group. The decline in
MMSE in the non-responders was significantly greater than in the
placebo group (P < 0.05).
Lloret 2009 reported a negative correlation between change in
MMSE score and change in blood levels of GSSG from baseline
to six months; that is, there was a greater decline in cognitive per-
formance in AD patients whose blood GSSG levels stayed higher
(reflecting higher oxidative stress).
No data were presented with regards to the effects of vitamin E
on cognitive measures in the treated group as a whole compared
to the placebo group. Subgroups could not be combined as data
were reported as statistical changes only and the data set was not
made available.
MCI and the prevention of progression of cognitive
impairment
The prevention study (Petersen 2005) had three treatment groups
of people withMCI, but only data from the vitamin E and placebo
groups were evaluated. The donepezil group was excluded.
The primary outcome was the time to the development of possible
or probable AD. Petersen 2005 reported that over the three years
of the trial, there was no significant difference in the probability
of progression from MCI to AD on the basis of Cox analysis
between the vitamin E group and placebo group (HR 1.02; 95%
CI 0.74 to 1.41; P = 0.91). The 36-month analysis was followed
by a pre-specified assessment of the treatment effects at each six-
month evaluation point. This analysis showed that there was no
significant difference between vitamin E and placebo groups on
the primary outcome at any time point measured during the trial.
A total of 38 subjects (out of 259) in the placebo group and 33
subjects (out of 257) in the vitamin E group had progression to
AD in the first 12 months. By 36 months, the numbers of subjects
with progression toADdid not differ, with 73 in the placebo group
and 76 in the vitamin E group. Although subjects were assessed at
6, 12, 18, 24, 30 and 36 months, numbers were only reported for
12 and 36 months; for the remainder only changes from baseline
were reported.
A total of 138 subjects discontinued treatment in the placebo
group (N = 72) and the vitamin E group (N = 66). The leading
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reasons for dropout were death, adverse events and withdrawal of
consent. However, there was no information on the distribution
of reasons for dropout across groups. The authors carried out sen-
sitivity analysis and z-testing to assess the effect of missing data as a
result of dropouts and concluded that the results of these analyses
were non-significant.
Changes in cognitive function scores from baseline to each of the
six-monthly time points were reported in both vitamin E and
placebo groups. No significant increases in any cognitive domain
scores were reported compared to baseline in the placebo group.
There were a few differences compared to baseline in the vitamin
E group and those that were seen (in the executive, language and
overall cognitive scores) were confined to the first 18 months of
the study. Specifically, executive function was significantly greater
at six months compared to baseline in the vitamin E group (P
< 0.05). Language scores were significantly greater compared to
baseline in the vitaminE group at sixmonths (P <0.05), 12months
(P < 0.05) and 18 months (P < 0.05). Overall cognitive scores
in the vitamin E group were significantly greater at six months
compared to baseline (P < 0.01). No between-group comparisons
were reported for the secondary outcomes.
D I S C U S S I O N
Three studies met the inclusion criteria and were selected for this
review. To our knowledge there are currently no relevant ongoing
trials. Two studies (Lloret 2009; Sano 1996) assessed the efficacy
of vitamin E in AD patients while one study (Petersen 2005) as-
sessed vitamin E in MCI patients. A significant limitation of this
review is that synthesis of data from the AD studies was not pos-
sible owing to different outcome measures. The primary outcome
measures from the Lloret 2009 studywere performance-based cog-
nitive tasks. Conversely the primary outcome measure in the Sano
1996 study was reaching a series of clinical end points. It would
not have been appropriate to pool data from the MCI study with
those from the AD studies as the MCI study evaluated a distinct
diagnostic entity.
There was no strong evidence that vitamin E when compared to
placebo was efficacious in improving outcomes of AD. In the Sano
1996 study there was no significant difference between vitamin E
and placebo group when using unadjusted data, although adjusted
data presented showed a significant delay to the primary end point.
Lloret 2009 implemented very different outcome measures com-
pared to Sano 1996, measuring changes in cognitive performance
as opposed to an end point index. Performance change was com-
pared between responders and non-responders (as determined by
the degree of change in markers of oxidative stress, defined post
hoc) and a placebo group. The Lloret 2009 study has opened a new
research avenue for studying the response to vitamin E among dif-
ferent patient subgroups. We agree with Brewer 2010 and Lloret
2009 that future research should also include concomitant mea-
surement of antioxidants and oxidative stress markers. However,
the Lloret 2009 study itself needs to be considered exploratory in
nature. The mechanisms that may explain why only a proportion
of patients respond ’oxidatively’ to the antioxidant vitamin E re-
mains unknown. Another significant limitation is the small num-
ber of participants, which made the subsequent subgroup analy-
sis less informative. A further limitation is the high drop-out rate
reported. Notwithstanding the limitations of this study, in those
patients where vitamin E did not reduce oxidative stress there was
a paradoxical accelerated decline in cognitive abilities compared
to placebo. Hence, additional caution is needed in the design of
future clinical trials utilising vitamin E treatment.
Petersen2005 foundnodifference in the probability of progression
fromMCI to AD between the vitamin E group and placebo group
during the three years of the study. Therefore the investigators
carried out a pre-specified assessment of the treatment effect at each
six-month evaluation point. The analysis confirmed that there
was no significant difference between the vitamin E and placebo
groups at any time during the trial. Vitamin E was also shown
to have very limited efficacy of improving cognitive outcomes in
a few cognitive domains. All cognitive improvements dissipated
after 18 months of treatment. Conclusions are necessarily limited
because no between-group analysis was conducted.
Old age is associatedwith vitaminE deficiency (Dror 2011).How-
ever, there is a difference between addressing deficiency with ade-
quate daily recommended levels and the use of high or very high
doses of vitamin E. The latter is much more likely to produce
significant side effects. High doses of alpha-tocopherol also have
potential to induce enzymes involved in drug metabolism with
an associated risk of serious interactions with some concomitant
medication (Brigelius-Flohé 2007).
Vitamin E assessed in epidemiological studies in relation to cog-
nition has consisted of the various naturally occurring forms
(Engelhart 2002; Morris 2002; Morris 2005). These studies have
generally reported a positive association between intake of vita-
min E and cognition. Morris 2005 suggested that the combined
intake of tocopherols is likely to be more important than alpha-
tocopherol alone. This is further supported byMangialasche 2010
who studied the relationship between cognitive impairment and
the eight individual forms of vitamin E and concluded that any
potential neuroprotective effect for vitamin E may result from in-
teraction of various forms. In addition to the forms of vitamin E
used, the potential biological benefits of vitamin E did not trans-
late to an effective treatment of AD and MCI possibly owing to
the relatively short intervention period.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
This review found no evidence for efficacy of vitamin E in the
treatment of AD. Taken together with other evidence that vitamin
E, especially in the large doses used in the included studies, may
be associated with potentially significant side effects and even an
increased rate of all-cause mortality (Miller 2005), we conclude
that vitamin E should not be used in the treatment of AD. We
consider it important to educate patients, carers and professionals
alike about the lack of confirmed efficacy and the potential hazards
of using vitamin E in AD. It is important to note that the efficacy
conclusions are based only on the alpha-tocopherol formulation
of vitamin E, and hence no comment can be made on the efficacy
of other preparations.
Implications for research
Vitamin E is a powerful antioxidant and plays an important role in
protecting cells against the harmful effects of free radicals. There
is sufficient evidence from laboratory and animal studies to justify
human investigation of this medicinal product for AD patients.
However, there continues to be a paucity of RCTs investigating
the efficacy of vitamin E in AD. The study of Lloret, which met
the inclusion criteria for this study, is of interest as it showed a
harmful effect on the cognition in those patients whose oxidative
stress markers did not respond to vitamin E intake (Lloret 2009).
However, the high number of drop-outs in this study limits the
conclusions that can be made. Findings are in need of replication
from sufficiently powered clinical trials incorporating the assess-
ment of oxidative stress markers in order to understand further
the oxidant-antioxidant balance in relation to vitamin E effects on
AD. In addition, the exclusive use of the alpha-tocopherol form
of vitamin E in clinical trials has been questioned. Therefore, fu-
ture studies must not restrict treatment to alpha-tocopherol, and
should investigate other tocopherol and tocotrienol forms. Future
updates of this review will specify sub-groups by vitamin E for-
mulation and oxidative stress response.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Lloret 2009
Methods Randomised, placebo-controlled, double-blind study
Participants Country: Spain
Single centre
Diagnosis: probable AD according to NINCDS-ADRDA
Number of participants: 57 patients, 18 healthy controls
Age: not stated
Inclusion criteria: not stated
Exclusion criteria: patients taking antioxidant supplements, patients taking any medica-
tion other than cholinesterase inhibitors
Severity of patients based on the Geriatric Dementia Scale - mild (N = 25), moderate
(N = 26) and severe (N = 6)
Interventions 6-month intervention
1. Vitamin E (800 IU/day)
2. Placebo daily
Outcomes 1. Clock drawing
2. BDS
3. MMSE
4. Oxidative stress levels
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned to groups
using a randomised list of numbers
Allocation concealment (selection bias) Unclear risk No reference was made to allocation con-
cealment was ensured
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Though it is a double-blinded study, and
random assignment occurred before the
trial, there is no mention of how/if partici-
pants and personnel were blinded through-
out
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Although it states it is a double-blinded
study, there is no indication to whether the
assessors were blinded
17Vitamin E for Alzheimer’s dementia and mild cognitive impairment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lloret 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk A total of 24/57 AD participants did not
complete the research. “Of the patients
who finished the study, 14 had been treated
with placebo and 19 with vitamin E.” The
reason for participant drop-out was not de-
scribed
Selective reporting (reporting bias) Unclear risk All outcomes reported sufficiently
Other bias Low risk No evidence of additional bias
Petersen 2005
Methods Randomised, placebo-controlled, double-blind study
Participants Country: US and Canada
Multicentre
Diagnosis: amnestic type of MCI
Subjects: 769 (46% females)
Age: 55 to 90 years, mean 73 years
Inclusion criteria: amnestic MCI of a degenerative nature, impaired memory, a Logical
Memory delayed-recall score approximately 1.5 to 2 SD below an education adjusted-
norm, a CDR of 0.5, a score of 24 to 30 on the MMSE, and an age of 55 to 90 years.
Adequate vision and hearing for neuropsychological testing, normal vitamin B12 and
thyroid function studies and non-reactive RPR. ECG normal or no clinical significant
abnormalities. Study informant available
Exclusion criteria: significant cerebral vascular disease, modified Hachinski > 4; Hamil-
ton Depression Rating Scale > 12; central nervous system infarct, infection or focal le-
sions of clinical significance on CT or MRI scan. Medical diseases or psychiatric disor-
ders that could interfere with study participation. Pregnant, lactating or of child bearing
potential; taking vitamin supplements, other supplements or multi-vitamin. Restriction
on concomitant medication usage, including those with significant cholinergic or anti-
cholinergic effects or potential adverse effects on cognition
Interventions Both vitamin E and donepezil were tested using a parallel group design, with 3 groups,
vitamin E group (vitamin E 2000 IU, placebo donepezil and a multivitamin daily),
donepezil group (donepezil 10 mg, placebo vitamin E and a multivitamin daily), and
placebo group (placebo vitamin E, placebo donepezil and a multivitamin daily). The
multivitamin contained vitamin E 15 IU
N.B. the initial dose of vitamin E was 1000 IU/day, and the dose was increased to 2000
IU (1000 IU twice daily) after 6 weeks
Outcomes 1. The time to possible or probable development of AD
2. MMSE
3. ADAS-Cog
4. Global CDR
5. ADCS Mild Cognitive Impairment Activities of Daily Living Scale
6. GDS
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Petersen 2005 (Continued)
7. Neuropsychological battery including; New York University paragraph-recall test, the
Symbol Digit Modalities Test, the category-fluency test, a number-cancellation test, the
Boston Naming Test, the digits-backward test, the Clock drawing test, and a maze-
tracing task
8. Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment of participants using
an adaptive allocation scheme with MMSE
score, age and APoE A4 status as a balanc-
ing covariates
Allocation concealment (selection bias) Unclear risk No reference was made to the method in
which allocation concealment was ensured
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants and personnel were blinded,
though no evidence was presented to sug-
gest if this was maintained throughout the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk There was no information presented about
how the study controlled for detection bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk This was an intention-to-treat analysis with
230 subjects withdrawing during the dou-
ble-blind phase and 539 subjects com-
pleting the double-blind or the open-label
phase, or both phases. A sensitivity analysis
was carried out that showed no significant
difference in the results regarding vitamin
E and placebo groups
Selective reporting (reporting bias) Low risk All outcomes reported sufficiently
Other bias Low risk No evidence of other bias
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Sano 1996
Methods Randomised, placebo-controlled, double-blind study
Duration: 2 years
Participants Country: US
Multicentre: 23 sites
Diagnosis: probable AD according to NINCDS-ADRDA
Number of subjects: 341 (65% females)
Age: mean 73 years
Inclusion criteria: CDR score: 2, Hachinski score > 4, dementia of moderate severity,
living at home with responsible carer, good general health
Exclusion criteria: neurological diagnoses other than AD, psychiatric DSM-III-R diag-
noses other than primary progressive dementia of Alzheimer’s type, recent history of psy-
choactive medication use, no antipsychotic/neuroleptic medications, no antidepressants
Interventions 1. Placebo
2. Vitamin E (2000 IU total daily dose divided into 2 doses)
3. Selegiline (10 mg total daily dose divided into 2 doses)
4. Vitamin E (2000 IU total daily dose divided into 2 doses) plus selegiline (10 mg total
daily dose divided into 2 doses)
Outcomes 1. Delay in any of 4 end points: death; institutionalisation; severity of dementia; loss of
activities of daily living
2. ADAS-Cog (Rosen 1984) evaluates cognition across 11 tests: spoken language ability,
comprehension of spoken language, recall of test instructions, word finding difficulty,
following commands, naming objects construction drawing, ideational praxis, orienta-
tion, word recall, and word recognition
3.MMSE (Folstein 1975) evaluates cognition in five areas; orientation, immediate recall,
attention and calculation, delayed recall and language
4. BDS (Blessed 1968) is composed of a series of scales split into 6 sections: the first 3
measure changes in performance of everyday activities, habits, personality, interests and
drive. The second 3 sections form the cognitive test
5. DS (Stern 1994), a 7-point scale that rates the need for care and supervision
6. BRSD (Tariot 1995). The BRSD measures psychopathological signs and symptoms
frequently seen in mild to moderate dementia. The covers the domains of depressive
features, psychotic features, defective self-regulation, irritability and agitation, vegetative
features, apathy, aggression and affective lability
7. Adverse events
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random assignment of patients followed
stratification according to centre using a
permuted-block procedure. This is one of
the most widely used sequential allocation
procedure and is designed to achieve stra-
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Sano 1996 (Continued)
tum balance. This method ensures an equal
distribution of all variables in the different
groups
Allocation concealment (selection bias) Unclear risk The method in which allocation conceal-
ment was ensured was not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants and personnel were blinded
prior to the beginning of trial. No reference
is made to whether they remained blinded
throughout
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk There was no reference of how the outcome
assessors were blinded to the allocated con-
dition
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up was defined as those who
did not reach an end point and did not
complete the study: 6/84 for the placebo
group and 8/85 for the vitamin E group,
4/87 for selegiline and 5/85 for vitamin E
plus selegiline. The reasons for withdrawal
were not described in each treatment group
Selective reporting (reporting bias) Low risk All outcome measures were reported
Other bias Low risk No evidence of other bias
AD: Alzheimer’s dementia; ADAS-Cog: Alzheimer’s Disease Assessment Scale - Cognitive section; ADCS: Alzheimer’s Disease Coop-
erative Study; APoE: apolipoprotein E; BDS: Blessed Dementia Scale; BRSD: Behavior Rating Scale for Dementia; CDR: Clinical
Dementia Rating; CT: computer tomography; DS: Dependence Scale; DSM-III-R: Diagnostic and Statistical Manual of Mental
Disorders, Third Edition; ECG: electrocardiography; GDS: Global Deterioration Scale; MCI: mild cognitive impairment; MMSE:
Mini-Mental State Examination; MRI: magnetic resonance imaging; NINCDS-ADRDA: National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association; RPR: rapid plasmin reagin;
SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alzoubi 2012 Sample population did not have a diagnosis of MCI or AD
Anand 2011 Sample population did not have a diagnosis of MCI or AD
Biesalski 2010 Review
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(Continued)
Bittner 2009 Retrospective design
Brewer 2010 Review
Carlsson 2002 Sample population did not have a diagnosis of MCI or AD
Chan 2008-2009 Used a nutriceutical formulation and there was no placebo
Chan 2010 Used a nutriceutical formulation. Placebo was just inert ingredients
Clarke 2003 Vitamin E was used in conjunction with vitamin C
It examined the association of cognitive impairment with platelet activation and reactive oxygen species
and total homocysteine levels
Cornelli 2010 Used a nutriceutical formulation, not vitamin E separately
Dysken 2009 No vitamin E intervention, just a questionnaire
Geldmacher 2011 Pioglitazone was the primary intervention. Placebo was administered alongside vitamin E
Guan 2012 The study did not have relevant outcome measures
Gutierrez 2009 Sample population did not have a diagnosis of MCI or AD
Jacoby 2002 Pilot study, compared aspirin to vitamin E (600 mg) in conjunction with vitamin C and placebo
Jae 2006 Vitamin E intervention given to healthy elderly women
Joshi 2012 Review
Kamat 2008 Literature review about antioxidants
Kesse-Guyot 2011 Sample population did not have a diagnosis of MCI or AD
Kesse-Guyot 2011a Sample population did not have a diagnosis of MCI or AD
Lee 2010 Literature review about antioxidants
Lott 2011 Sample population had a diagnosis of Down’s syndrome and dementia
Lu 2009 Focus of intervention was towards depressed vs. non-depressed MCI population
MacPherson 2012 Sample population did not have a diagnosis of MCI or AD
Mecocci 2012 Review
Onofrj 2002 Vitamin E compared to donepezil not placebo
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(Continued)
Pavlik 2009 Retrospective in nature. No controls or placebo group
Pribis 2012 Did not use vitamin E as an intervention
Péneau 2011 Not a randomised double-blinded study; investigated the intake of fruits and vegetables
Remington 2009 Used a nutriceutical formulation and the placebo was inert
Schmitt 2009 Used a healthy population
Schneider 2009 Same data as Petersen 2005
Takahashi 2009 Case study, no placebo and no controls
Usoro 2010 Review
Vinyoles-Bargallo 2010 Not an original paper, just a personal comment
Whitehair 2010 Same data as Petersen 2005
AD: Alzhimer’s dementia; MCI: mild cognitive impairment.
Characteristics of ongoing studies [ordered by year of study]
NCT01320527
Trial name or title A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer’s Disease
Methods
Participants Alzheimer’s dementia and mild cognitive impairment. Must be able to swallow pills. Must not have a known
or suspected bipolar disorder
Interventions Nutriceutical formulation
Outcomes 1. Cognitive performance
2. Behavioural/psychotic symptoms
Starting date August 2008
Contact information Contact: Ruth Remington, Ph.D.
978-934-4423
Ruth remington@uml.edu
Contact: Thomas B Shea, Ph.D.
978 934-2881
thomas shea@uml.edu
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NCT01320527 (Continued)
Notes Not likely to be relevant to future reviews as it uses a Nutriceutical formulation
Markesbery 2002
Trial name or title Prevention of Alzheimer’s Disease by Vitamin E and Selenium
Methods
Participants Healthy volunteers, 60 to 90 years of age excluding Alzheimer’s dementia, or any other form of dementia,
Huntington’s disease, epilepsy, Parkinson’s disease, brain tumour, multiple sclerosis, manic-depressive disorder
or schizophrenia; head injury with over 30 minutes’ loss of consciousness within last 5 years; current alcohol
or substance abuse; depression or anxiety disorder in the past 4 months or under treatment for depression
or anxiety; using Aricept (donepezil), Cognex (tacrine), Exelon (rivastigmine), Reminyl (galantamine) or
Hydergine (dihydroergotoxine); disabilities that may prevent completion of memory screen
Interventions Vitamin E and selenium
Outcomes Developing Alzheimer’s disease, memory impairment
Starting date May 2002 to 2003
Contact information Cecil R. Runyons: 001 859 257 1412 Ext. 235; email: preadvise@1sv.uky.edu
William Markesbery, Principle Investigator, Alzheimer’s Disease Research Center, Sanders-Brown Center on
Aging, University of Kentucky, Lexington, KY 40536, USA. wmark0@email.uky.edu
Notes Expected total enrolment 10,400. Same participants of the SELECT (Selenium and Vitamin E Cancer
Prevention Trial) study looking at use of vitamin E and selenium for prevention of prostate cancer. Estimated
completion August 2012. This trial is likely to be ineligible as participants are healthy controls
NCT00056329 2000
Trial name or title Multicenter Vitamin E Trial in Aging Persons With Down Syndrome
Methods Interventional
Participants Clinically determined Down’s syndrome (karyotypes optional), aged 50 years or older at the start of the
protocol
Interventions 1000 UI alpha-tocopherol tice daily
Outcomes Primary outcome measures:
• Brief Praxis test
Secondary outcome measures:
• Fuld Object Memory test
• New Dot test
• Orientation test
• Vocabulary test
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NCT00056329 2000 (Continued)
• Behaviour and Function
• Clinical Global Impression
• Incident Dement
Starting date September 2000
Contact information Arthur Dalton
Deputy Director
New York State Institute for Basic Research
daltonaj@aol.com
Notes Not relevant for future reviews as it uses a Down’s syndrome population
Gopal 2005
Trial name or title Effects of Vitamin E on Cognition and Measures of Activities of Daily Living in Patients with Moderately
Severe Alzheimer’s Disease
Methods
Participants Patients with moderately severe Alzheimer’s disease
Interventions Vitamin E 500 mg twice daily with cholinesterase inhibitors
Outcomes Changes in cognition and activities of daily living
Starting date 1 November 2002
Contact information Dr Vishnu Gopal
Argyll House
9 Williamson Road, Nether Edge
Sheffield S11 9AR
telephone 0114 2718656
Fax: 01142716643
vgopal@doctors.org.uk
Notes Study topic and author searched online, no evidence of trial or published data. Author no longer at contact
address, emailed for an update but no response
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Source, search strategy and hits retrieved: June 2012 search
Source Search strategy Hits received
1. ALOIS (www.medicine.ox.ac.uk/alois) Advanced search: [Study design: RCT OR
CCT] AND [Health condition: Alzheimer
OR MCI] AND [Intervention: “vitamin
E”] (all dates)
June 2012: 39 (all dates)
2. MEDLINE In-process and other non-
indexed citations and MEDLINE 1950 to
present (Ovid SP)
1. *Vitamin E/
2. “vitamin E”.ti,ab.
3. “alpha-tocopherol”.ti,ab.
4. or/1-3
5. Alzheimer*.ti,ab.
6. Alzheimer Disease/
7. AD.ti,ab.
8. “cognit* impair*”.ti,ab.
9. MCI.ti,ab.
10. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
11. (“N-MCI” or “A-MCI” or “M-MCI”)
.ti,ab.
12. (nMCI or aMCI or mMCI).ti,ab.
13. (CDR adj2 “0.5”).ab.
14. or/5-13
15. 4 and 14
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. randomi?ed.ab.
19. placebo.ab.
20. drug therapy.fs.
21. randomly.ab.
22. trial.ab.
23. groups.ab.
24. or/16-23
25. (animals not (humans and animals)).
sh.
26. 24 not 25
27. 15 and 26
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(Continued)
3. EMBASE
1980 to 2011 week 27 (Ovid SP)
1. *Vitamin E/
2. “vitamin E”.ti,ab.
3. “alpha-tocopherol”.ti,ab.
4. or/1-3
5. Alzheimer*.ti,ab.
6. Alzheimer Disease/
7. AD.ti,ab.
8. “cognit* impair*”.ti,ab.
9. MCI.ti,ab.
10. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
11. (“N-MCI” or “A-MCI” or “M-MCI”)
.ti,ab.
12. (nMCI or aMCI or mMCI).ti,ab.
13. (CDR adj2 “0.5”).ab.
14. or/5-13
15. 4 and 14
16. randomi?ed.ab.
17. placebo.ab.
19. trial.ab.
20. groups.ab.
21. randomized controlled trial/
22. controlled clinical trial/
23. (“double-blind*” or “single-blind*”).ti,
ab.
24. or/16-23
25. 15 to 24
June 2012: 28
4. PsycINFO
1806 to July week 2 2011 (Ovid SP)
1. “vitamin E”.ti,ab.
2. “alpha-tocopherol”.ti,ab.
3. Alzheimer*.ti,ab.
4. Alzheimer Disease/
5. AD.ti,ab.
6. “cognit* impair*”.ti,ab.
7. MCI.ti,ab.
8. (AACI or memory or CIND or ARCD
or ACMI).ti,ab.
9. (“N-MCI” or “A-MCI” or “M-MCI”).
ti,ab.
10. (nMCI or aMCI or mMCI).ti,ab.
11. (CDR adj2 “0.5”).ab.
12. randomi?ed.ab.
13. placebo.ab.
14. randomly.ab.
15. trial.ab.
16. groups.ab.
17. (“double-blind*” or “single-blind*”).ti,
ab.
18. Clinical Trials/
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(Continued)
19. 1 or 2
20. or/3-11
21. or/12-18
22. 19 and 20 and 21
5. CINAHL (EBSCOhost) S1 (MM “Vitamin E”)
S2 TX “vitamin E”
S3 TX “alpha-tocopherol”
S4 S1 or S2 or S3
S5 (MH “Alzheimer’s Disease”)
S6 TX AD OR alzheimer*
S7 “mild cognitive impairment”
S8 TX “cognit* impair*”
S9 TX AACI OR memory OR CINDOR
ARCD OR ACMI
S10 TX MCI
S11 TX nMCI OR aMCI OR mMCI
S12 S5 or S6 or S7 or S8 or S9 or S10 or
S11
S13 S4 and S12
S14 TX random*
S15 TX placebo*
S16 TX trial
S17 TX groups
S18 TX RCT OR CCT
S19 (MH “Randomized Controlled Tri-
als”)
S20 S14 or S15 or S16 or S17 or S18 or
S19
S21 S13 and S20
S22 EM 2009
S23 EM 2010
S24 EM 2011
S25 S22 or S23 or S24
S26 S21 and S25
June 2012: 6
6. ISIWeb of Knowledge - all databases [in-
cludes: Web of Science (1945 to present);
BIOSIS Previews (1926 to present);MED-
LINE (1950 to present); Journal Citation
Reports]
#1 Topic=(alzheimer* OR AD OR MCI
OR memory OR cognitive OR “cognit*
impair*”) AND Topic=(“vitamin e” OR
“alpha-tocopherol”) AND Year Published=
(2009-2011)
Timespan=All Years
#2 Topic=(random* OR placebo* OR
“double-blind*” OR “single-blind*”)
Timespan=All Years
#3 #2 AND #1
Timespan=All Years
June 2012: 174
7. LILACS (BIREME) vitamin-e OR alpha-tocopherol June 2012: 0
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(Continued)
8. CENTRAL (The Cochrane Library) (Is-
sue 4 of 4, Oct 2010)
#1 “vitamin e”
#2 “alpha-tocopherol”
#3 (#1 OR #2)
#4 MeSH descriptor Vitamin E, this term
only
#5 (#3 OR #4)
#6 alzheimer* OR AD OR “cognit* im-
pair*” OR MCI
#7 (#5 AND #6), from 2011 to 2012
June 2012: 9
9. Clinicaltrials.gov (
www.clinicaltrials.gov)
Interventional Studies | alzheimer OR
alzheimer’s OR alzheimers OR MCI OR
cognitiveOR cognitionORmemory | vita-
minEORalpha-tocopherol | received from
01/01/2011 to 07/15/2012
June 2012: 2
10. ICTRP Search Portal (apps.who.int/
trialsearch) (includes: Australian New
Zealand Clinical Trials Registry; Clinical-
Trilas.gov; ISRCTN;Chinese Clinical Trial
Registry; Clinical Trials Registry - India;
Clinical Research Information Service - Re-
public of Korea; German Clinical Trials
Register; Iranian Registry of Clinical Tri-
als; Japan Primary Registries Network; Pan
African Clinical Trial Registry; Sri Lanka
Clinical Trials Registry; The Netherlands
National Trial Register)
Interventional Studies | alzheimer OR
alzheimer’s OR alzheimers OR MCI OR
cognitiveOR cognitionORmemory | vita-
minEORalpha-tocopherol | received from
01/07/2011 to 15/07/2012
June 2012: 2
TOTAL before de-duplication 282
TOTAL after de-duplication and first assessment 14
WH A T ’ S N E W
Last assessed as up-to-date: 25 June 2012.
Date Event Description
25 June 2012 New citation required and conclusions have changed An update search was performed for this review on 15 July
2011 and 25 June 2012. One additional study was included
(Lloret 2009); the results and conclusions have changed. The
authors of the review have changed
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H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 4, 2000
Date Event Description
15 July 2011 New search has been performed An update search was performed for this review on 15
July 2011
18 March 2009 New search has been performed Update search of 5 March 2009 retrieved new studies
for consideration for inclusion
25 April 2008 New citation required but conclusions have not
changed
In 2007, the scope of this review was broadened to
include both Alzheimer’s disease patients and patients
with mild cognitive impairment
16 January 2007 New search has been performed Update 2007: one new study was included (Petersen
2005). The included study did not affect the results
as it also showed that vitamin E has no more signifi-
cant effect than placebo formild cognitive impairment.
The overall conclusion of the review has not changed
as there is not enough evidence to support the use of
vitamin E in the treatment of Alzheimer’s disease or
mild cognitive impairment
2 November 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Original: NT drew up the protocol. MI planned the review and protocol, selected studies, critiqued the trials, advised on analyses,
revised drafts of protocol and review and supervised the review process. AS assisted in devising the protocol, searched the literature, co-
reviewed studies and revised drafts of the paper.
Update 2006: MI and RQ reviewed and selected the included studies. MI extracted the data, performed the analysis and wrote the
draft. NT contributed to the text and supervised. The search was carried out by Dymphna Hermans.
Update 2011: NF and MI reviewed and selected the included studies. NF extracted the data and wrote the draft. AC, JR and NT
contributed to the text. JR and NT supervised. The search was carried out by Anna-Noel Storr.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• School of Psychology, University of Sussex, UK.
External sources
• NHS R&D, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The methods of the review were adapted to include the subgroup analysis of those that did (’responders’) and did not (’non-responders’)
report a decline in oxidative stress as a result of a vitamin E intervention. This adaptation was decided on the basis that the primary
mechanism for vitamin E is to act as an antioxidant and hence it is important to determine whether the intervention is achieving its
desired results.
The methods of the review were updated to comply with the most recent version of the Cochrane Handbook for Systematic Reviews of
Interventions (Version 5.1; Higgins 2011).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Alzheimer Disease [∗drug therapy]; Antioxidants [∗therapeutic use]; Disease Progression; Mild Cognitive Impairment [∗drug therapy];
Outcome Assessment (Health Care); Randomized Controlled Trials as Topic; Vitamin E [∗therapeutic use]
MeSH check words
Humans
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